Skip to main content
. 2018 Jul 20;1(3):e180769. doi: 10.1001/jamanetworkopen.2018.0769

Table 4. Patient Characteristics and Outcome by Different Subgroups.

Variable All Patients, No. (%) (N = 36) Patients, No.
Favorable Neuroimaging Unfavorable Neuroimaging
Bone Marrow (n = 11), Group Ia Peripheral Stem Cells or Cord Blood (n = 7), Group Ib With Demyelination of Cerebellum or Basal Ganglia (n = 4), Group IIa Other MRI (n = 14), Group IIb
Neurological status at HSCT
Presymptomatic 18 (50) 10 7 0 1
NFS ≤1a 29 (81) 11 7 2 9
ALD-DRS = 0a 20 (56) 10 7 1 2
Neuroimaging before HSCT
Loes score ≥9a 8 (22) 0 0 1 7
Parieto-occipital pattern 22 (61) 9 7 0 6
Projection fibers involved 21 (58) 4 1 3 13
Transplant characteristics
Transplant before 2004 21 (58) 4 4 4 9
Related donor 9 (25) 5 0 0 4
Bone marrow 26 (72) 11 0 3 12
Engraftment before day 14 after HSCT 16 (44) 4 4 1 7
Donor chimerism >95% 31 (89)b 9b 7 3 12
Infection grade >2 14 (39) 2 3 2 7
Acute GVHD grade ≥2 9 (25) 0 2 2 5
Outcome
Transplant-related deaths 3 (8) 0 2 0 1
Disease-related deaths 6 (17) 0 0 4 2
Major functional disabilities 10 (28) 0 0 4 6
Event-free survivors 14 (39) 11 3 0 0
Event-free survival time, median (IQR), moc 26 (9-60) 104 (45-121) 38 (17-132) 6 (2.5-9.2) 10 (4.8-22)

Abbreviations: ALD-DRS, adrenoleukodystrophy disability rating score; GVHD, graft-vs-host disease; HSCT, hematopoietic stem cell transplantation; IQR, interquartile range; MRI, magnetic resonance imaging; NFS, neurological function score.

a

ALD-DRS range, 0-4 points; NFS range, 0-25 points (NFS ≤1: score with maximum 1 deficit); and Loes MRI score range, 0-34 points. For all scores: 0 indicates no abnormalities, and higher numbers indicate worsening status.

b

Donor chimerism: determined in only of 35 patients (1 patient from group Ia was missing).

c

Kaplan-Meier estimates.